Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Shareholders for Collegium Pharmaceutical, Inc., held on May 18, 2023. The record date for the meeting was March 31, 2023. The company is incorporated in Virginia and its common stock trades on the NASDAQ Global Select Market under the symbol COLL.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder voting results. It does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the company's most recent Form 10-K or 10-Q for financial performance details.
Material Changes and Voting Results
A total of 34,581,020 shares were entitled to vote, with 30,815,695 shares present in person or by proxy. The following proposals were approved:
- Proposal 1 (Election of Directors): All nine nominees were re-elected to serve until the 2024 Annual Meeting. While all were approved, nominees John Fallon and Michael Heffernan received a higher number of "Against" votes compared to other directors.
- Proposal 2 (Executive Compensation): Shareholders approved, on an advisory basis, the compensation of the named executive officers.
- Proposal 3 (Auditor Ratification): Shareholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
Guidance, Outlook, and Risks
This filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is strictly a disclosure of shareholder voting outcomes.
Key Facts for Investor Verification
- Verify the specific vote counts for directors John Fallon and Michael Heffernan, who received significantly more "Against" votes than their peers.
- Confirm the total number of broker non-votes (2,455,884) which did not affect the outcome of the director election but were recorded.
- Review the company's latest quarterly or annual report for financial health indicators, as this 8-K contains no financial data.
- Note that the fiscal year-end for the ratified auditor is December 31, 2023.